Dr. Drasga studies several key areas in medicine, particularly focusing on cancer therapeutics and the educational tools used in occupational therapy. He investigates treatment effectiveness for various cancers, including advanced prostate cancer and non-small-cell lung cancer, evaluating how different drug combinations can impact patient outcomes. Additionally, he researches the performance evaluation methods that occupational therapy programs use, ensuring that students are well-prepared for their careers by improving educational standards. His work aims to make both cancer treatments more effective and the training processes in occupational therapy more robust.
Key findings
In a study on occupational therapy evaluations, 32 out of 37 items for students and 27 out of 31 items for assistants showed strong validity, enhancing training quality.
For patients with hormone-refractory prostate cancer, the addition of doxorubicin and methotrexate provided a slight survival improvement with a median survival of 9.5 months compared to 9 months for those receiving only cyclophosphamide, although not statistically significant.
In treating favorable-prognosis disseminated germ cell tumors, using three cycles of chemotherapy achieved a 98% disease-free rate, similar to the 97% rate from four cycles, thus reducing side effects.
A study on non-small-cell lung cancer showed that the combination of vindesine and cisplatin resulted in a 27% response rate compared to 14% with vindesine alone, though overall survival didn’t differ significantly.
Frequently asked questions
Does Dr. Drasga study prostate cancer?
Yes, Dr. Drasga has researched treatments for hormone-refractory prostate cancer and their effectiveness.
What treatments has Dr. Drasga researched for lung cancer?
He studied various drug combinations for advanced non-small-cell lung cancer, comparing their effectiveness.
Is Dr. Drasga's work relevant to occupational therapy students?
Absolutely, his research focuses on improving the evaluation methods used in occupational therapy training programs.
What are the benefits of Dr. Drasga's chemotherapy research?
His studies have identified less intensive chemotherapy regimens that maintain effectiveness while minimizing side effects for patients.
Publications in plain English
The Revised American Occupational Therapy Association Fieldwork Performance Evaluations: Evaluation of Internal Structure, Response Processes, and Precision-Part 2.
2023
The American journal of occupational therapy : official publication of the American Occupational Therapy Association
Kottorp A, Killian C, Duke K, Leggett C, Drasga R +1 more
Plain English This research studied the updated evaluation tools used to assess the performance of students in occupational therapy and occupational therapy assistant programs. They found that the new evaluation tools showed strong evidence of validity, with 32 out of 37 items for occupational therapy students and 27 out of 31 items for assistant students fitting the criteria well. This is important because it means these revised tools can effectively measure students' performance, enhancing the quality of training in occupational therapy programs.
Who this helps: This helps students in occupational therapy and their educators.
Activity Engagement and Everyday Technology Use Among Older Adults in an Urban Area.
2018
The American journal of occupational therapy : official publication of the American Occupational Therapy Association
Walsh R, Drasga R, Lee J, Leggett C, Shapnick H +1 more
Plain English The study looked at how older adults in a city engage in activities and use everyday technology. Researchers found that those who participated in more activities had access to a greater number of useful technologies, with significant differences (p < .001) between different activity levels. However, their ability to use these technologies didn’t differ based on their activity engagement, and their cognitive status didn’t affect their activity level when considering the technology available. Making everyday technology more accessible for older adults can help them engage more in daily activities.
Who this helps: This helps older adults and their caregivers.
Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study.
1992
Cancer
Saxman S, Ansari R, Drasga R, Miller M, Wheeler B +2 more
Plain English This study compared two treatment options for patients with advanced prostate cancer that didn't respond to hormone therapy. Researchers looked at 103 patients, with one group receiving only cyclophosphamide and the other group receiving cyclophosphamide along with two other drugs, doxorubicin and methotrexate. The results showed that adding doxorubicin and methotrexate did not improve survival rates: patients taking just cyclophosphamide had a median survival of 9 months, while those on the combination had a median survival of 9.5 months, and the difference was not significant.
Who this helps: This research helps doctors determine the most effective treatments for patients with hormone-refractory prostate cancer.
Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.
1989
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R +2 more
Plain English This study looked at how many courses of chemotherapy are needed for patients with a type of cancer called favorable-prognosis disseminated germ cell tumors. Researchers compared giving patients either three or four courses of the standard treatment, PVP16B, and found that both groups achieved similar disease-free rates—98% for those receiving three courses and 97% for those receiving four courses. Reducing the treatment from four to three courses means less side effects, lower costs, and less hassle for patients.
Who this helps: This helps patients with disseminated germ cell tumors by offering a less intensive treatment option.
Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
1986
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T +5 more
Plain English This study looked at three different treatment combinations for patients with advanced non-small-cell lung cancer, comparing the effectiveness of the cancer drug vindesine alone to combinations of vindesine with cisplatin and mitomycin C. They found that the combination of cisplatin and vindesine resulted in a response rate of 27%, while vindesine alone had a response rate of 14%. However, there was no significant difference in overall survival between the groups, with patients on the cisplatin and vindesine treatment living a median of 26 weeks compared to 18 weeks for those on vindesine alone.
Who this helps: This research helps doctors understand the effectiveness of different treatment options for lung cancer patients.